Equities

Regenxbio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Regenxbio Inc

Actions
  • Price (EUR)6.65
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change-3.62%
  • Beta1.1100
Data delayed at least 15 minutes, as of Feb 17 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments235275365
Total Receivables, Net202528
Total Inventory------
Prepaid expenses9.071514
Other current assets, total14209.35
Total current assets278335416
Property, plant & equipment, net171193207
Goodwill, net------
Intangibles, net------
Long term investments1039201
Note receivable - long term0.470.701.50
Other long term assets4.004.816.40
Total assets466574833
LIABILITIES
Accounts payable232327
Accrued expenses465753
Notes payable/short-term debt000
Current portion long-term debt/capital leases345149
Other current liabilities, total0.120.151.83
Total current liabilities103130130
Total long term debt254389
Total debt6094138
Deferred income tax------
Minority interest------
Other liabilities, total788898
Total liabilities206262317
SHAREHOLDERS EQUITY
Common stock0.010.000.00
Additional paid-in capital1,1931,021973
Retained earnings (accumulated deficit)(932)(705)(442)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.74)(4.43)(15)
Total equity260312516
Total liabilities & shareholders' equity466574833
Total common shares outstanding504443
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.